title: Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.
authors.affiliation: Department I of Internal Medicine.
authors.forename: Bastian
authors.initials: B
authors.lastname: von Tresckow
authors.forename: Boris
authors.initials: B
authors.lastname: Boell
authors.forename: Dennis
authors.initials: D
authors.lastname: Eichenauer
authors.forename: Denissa
authors.initials: D
authors.lastname: Beschorner
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Maria-Elisabeth
authors.initials: ME
authors.lastname: Goebeler
authors.forename: Jens Marcus
authors.initials: JM
authors.lastname: Chemnitz
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Kai
authors.initials: K
authors.lastname: Huebel
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab